ライフサイエンスコーパス: irritable

1 Irritable/aggressive symptoms were present in 13.9% of t

2 The irritable and headstrong/hurtful dimensions of oppositio

3 rs after ingestion when she became confused, irritable, and agitated.

4 aments: hyperthymic, dysthymic, cyclothymic, irritable, and anxious.

5 a significant risk factor for postinfectious irritable bowel and chronic fatigue syndromes.

6 ructive pathologies of the two main forms of irritable bowel disease (IBD), ulcerative colitis (UC),

7 individuals, and those with colon cancer and irritable bowel disease (IBD), we demonstrated that CD4C

8 rylation was observed in colonic mucosa from irritable bowel disease patients.

9 centage of individuals with gastrointestinal/irritable bowel disease.

10 d may offer a therapeutic avenue in treating irritable bowel disease.

11 tive protease pathway in the pathogenesis of irritable bowel disease.

12 evels of comorbidity included migraine (33), irritable bowel syndrome (17), functional neurological d

13 The prevalences of irritable bowel syndrome (39.4%) by Rome III criteria an

14 ), 6.78% in Crohn's disease (4/59), 5.82% in irritable bowel syndrome (51/877), and 4.9% in the remai

15 subjects (aged 24-61 y, 6 men) with NCGS and irritable bowel syndrome (based on Rome III criteria), b

16 ota of patients with constipated-predominant irritable bowel syndrome (C-IBS) displays chronic dysbio

17 (FC), Gastrointestinal Symptoms Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) and Hospital Anxiety

18 he Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) into German and to e

19 red by Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome (GSRS-IBS) version.

20 also collected from 151 patients with CD or irritable bowel syndrome (IBS) (controls).

21 ed by the intestinal mucosa of patients with irritable bowel syndrome (IBS) affect the function of en

22 Irritable bowel syndrome (IBS) affects 7% to 21% of the

23 tudies have shown an increased prevalence of irritable bowel syndrome (IBS) after acute gastroenterit

24 patients (63.8%) had a previous diagnosis of irritable bowel syndrome (IBS) and 23 (28.8%) had one of

25 e Rome IV Diagnostic Questionnaire, Rome III irritable bowel syndrome (IBS) and constipation question

26 es from patients of colorectal cancer (CRC), irritable bowel syndrome (IBS) and controls to be run th

27 We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antag

28 symptoms, which occasionally mimic those of Irritable Bowel Syndrome (IBS) and Fibromyalgia Syndrome

29 hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal

30 tious gastroenteritis increases the risk for irritable bowel syndrome (IBS) and functional dyspepsia

31 ists are effective in treating patients with irritable bowel syndrome (IBS) and have anxiolytic effec

32 The clinical spectra of irritable bowel syndrome (IBS) and inflammatory bowel di

33 Irritable bowel syndrome (IBS) and inflammatory bowel di

34 Very few studies report on the prevalence of irritable bowel syndrome (IBS) and its correlates in the

35 Nowadays irritable bowel syndrome (IBS) and lactose intolerance (

36 Irritable bowel syndrome (IBS) and other functional bowe

37 isease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common functional gas

38 healthy children and pediatric patients with irritable bowel syndrome (IBS) are not well defined.

39 cture is used by patients as a treatment for irritable bowel syndrome (IBS) but the evidence on effec

40 Irritable bowel syndrome (IBS) can be responsible for al

41 Although novel therapies for irritable bowel syndrome (IBS) continue to be developed,

42 pathophysiology, diagnosis, and treatment of irritable bowel syndrome (IBS) convened to audit the cur

43 elationship between giardiasis diagnosis and irritable bowel syndrome (IBS) diagnosis.

44 suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) frequently overlap with t

45 Hypnotherapy for irritable bowel syndrome (IBS) has been used primarily i

46 Only a fraction of patients with irritable bowel syndrome (IBS) have increased perceptual

47 Patients with irritable bowel syndrome (IBS) have increased postprandi

48 odify pain end points in clinical trials for irritable bowel syndrome (IBS) highlights the knowledge

49 igenome, and transcriptome in the context of irritable bowel syndrome (IBS) host physiology.

50 and its degree of overlap with dyspepsia and irritable bowel syndrome (IBS) in Nigeria, a typical Afr

51 care consumption for patients diagnosed with Irritable Bowel Syndrome (IBS) in primary and secondary

52 Irritable bowel syndrome (IBS) is a chronic functional g

53 Irritable Bowel Syndrome (IBS) is a common condition cha

54 Irritable bowel syndrome (IBS) is a common functional ga

55 Irritable bowel syndrome (IBS) is a common gastrointesti

56 Irritable bowel syndrome (IBS) is a common gastrointesti

57 Irritable bowel syndrome (IBS) is a common, symptom-base

58 Irritable bowel syndrome (IBS) is a functional disorder

59 Irritable bowel syndrome (IBS) is a functional gastroint

60 Irritable Bowel Syndrome (IBS) is a functional somatic s

61 Irritable bowel syndrome (IBS) is a gut-brain disorder i

62 Irritable bowel syndrome (IBS) is a heterogeneous disord

63 Irritable bowel syndrome (IBS) is among the most common

64 BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is associated with intest

65 Irritable bowel syndrome (IBS) is characterized by abdom

66 Irritable bowel syndrome (IBS) is characterized by alter

67 Irritable bowel syndrome (IBS) is common but difficult t

68 Irritable bowel syndrome (IBS) is common, affecting 10-2

69 Irritable bowel syndrome (IBS) is more common in patient

70 Irritable bowel syndrome (IBS) is one of the most common

71 Irritable bowel syndrome (IBS) is prevalent in patients

72 Patients with irritable bowel syndrome (IBS) often relate symptoms to

73 Patients with Irritable Bowel Syndrome (IBS) often relate their sympto

74 role of the microbiota in the development of irritable bowel syndrome (IBS) only recently has been co

75 ) signaling pathways have been implicated in irritable bowel syndrome (IBS) pathophysiology.

76 HPA axis response to a visceral stressor in irritable bowel syndrome (IBS) patients and healthy cont

77 Syndrome (FMS) is a frequent comorbidity in Irritable Bowel Syndrome (IBS) patients with a higher fu

78 This study investigated Irritable Bowel Syndrome (IBS) prevalence in a sample of

79 The diagnosis of irritable bowel syndrome (IBS) relies on symptom-based c

80 Patients with irritable bowel syndrome (IBS) seen by a gastroenterolog

81 sorbed fermentable carbohydrates can provoke irritable bowel syndrome (IBS) symptoms by escaping abso

82 suspected food intolerances in patients with irritable bowel syndrome (IBS) using confocal laser endo

83 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

84 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

85 ders state that children suspected of having Irritable Bowel Syndrome (IBS) with Constipation (IBS-C)

86 ept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C)

87 treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea.

88 ciated with colonic transit in patients with irritable bowel syndrome (IBS) with diarrhea.

89 of PI sequelae among exposed was as follows: irritable bowel syndrome (IBS), 3.0; dyspepsia, 1.8; con

90 and male healthy subjects and patients with irritable bowel syndrome (IBS), a common chronic abdomin

91 d neural mechanisms are well-acknowledged in irritable bowel syndrome (IBS), a disorder of brain-gut-

92 ve been implicated in the pathophysiology of irritable bowel syndrome (IBS), a visceral pain syndrome

93 including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation

94 in patients with functional dyspepsia (FD), irritable bowel syndrome (IBS), and FD-IBS overlap.

95 s are abnormal in the ileum of patients with irritable bowel syndrome (IBS), and whether any abnormal

96 d genetic factors contribute to variation in irritable bowel syndrome (IBS), anxiety and depression.

97 Certain gut disorders, such as the irritable bowel syndrome (IBS), are associated with elev

98 ND & AIMS: Probiotics can reduce symptoms of irritable bowel syndrome (IBS), but little is known abou

99 bnormal gut-brain interactions are common in irritable bowel syndrome (IBS), but the associations bet

100 Peppermint oil is frequently used to treat irritable bowel syndrome (IBS), despite a lack of eviden

101 iated with three other functional disorders; irritable bowel syndrome (IBS), functional dyspepsia (FD

102 the area of functional GI syndromes such as irritable bowel syndrome (IBS), functional dyspepsia, an

103 ose was to evaluate the overlap frequency of irritable bowel syndrome (IBS), gastroesophageal reflux

104 on ultimate diagnosis: Crohn's disease (CD), Irritable bowel syndrome (IBS), NSAIDs enteritis (NSAIDs

105 een pathophysiologic factors and symptoms of irritable bowel syndrome (IBS), or whether these factors

106 In patients with irritable bowel syndrome (IBS), pain amplification and h

107 patients with functional dyspepsia (FD) and irritable bowel syndrome (IBS), respectively, as defined

108 Using CLE analysis of patients with irritable bowel syndrome (IBS), we found that more than

109 In irritable bowel syndrome (IBS), which is the most common

110 l gastrointestinal symptoms in patients with irritable bowel syndrome (IBS), yet there is limited evi

111 atory bowel diseases (IBD), the reporting of irritable bowel syndrome (IBS)-type symptoms by patients

112 the progression and evaluate the severity of irritable bowel syndrome (IBS).

113 Visceral hypersensitivity is one feature of irritable bowel syndrome (IBS).

114 ted to reduce symptoms in some patients with irritable bowel syndrome (IBS).

115 ociated with abdominal pain in patients with irritable bowel syndrome (IBS).

116 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

117 sing diet in the management of patients with irritable bowel syndrome (IBS).

118 effective in the treatment of patients with irritable bowel syndrome (IBS).

119 agonists might be involved in development of irritable bowel syndrome (IBS).

120 by mutations in SCN5A also have symptoms of irritable bowel syndrome (IBS).

121 have important roles in the pathogenesis of irritable bowel syndrome (IBS).

122 the pathophysiology of anxiety disorders and irritable bowel syndrome (IBS).

123 studies of existing diagnostic criteria for irritable bowel syndrome (IBS).

124 microbiota might also play a similar role in irritable bowel syndrome (IBS).

125 relieve symptoms for patients suffering from irritable bowel syndrome (IBS).

126 versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS).

127 important role in the pathophysiology of the irritable bowel syndrome (IBS).

128 used to treat patients with nonconstipating irritable bowel syndrome (IBS).

129 l nervous system is altered in patients with irritable bowel syndrome (IBS).

130 ial overgrowth (SIBO) may be associated with irritable bowel syndrome (IBS).

131 risk of gastrointestinal diseases including irritable bowel syndrome (IBS).

132 chologic dysfunction have been implicated in irritable bowel syndrome (IBS).

133 regulated in functional GI disorders such as irritable bowel syndrome (IBS).

134 rrhoea and chronic diarrhoea associated with irritable bowel syndrome (IBS).

135 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

136 hypersensitivity is common in patients with irritable bowel syndrome (IBS).

137 pulation each year, and is a risk factor for irritable bowel syndrome (IBS).

138 in, constipation, and bloating; diagnoses of irritable bowel syndrome (IBS); and tegaserod prescripti

139 alence of celiac disease among patients with irritable bowel syndrome (IBS); few data are available w

140 fies the FBDs into five distinct categories: irritable bowel syndrome (IBS); functional constipation

141 shown promise in alleviating the symptoms of irritable bowel syndrome (IBS); however, controlled data

142 and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism

143 compared to a milk product in subjects with irritable bowel syndrome (IBS, n = 28).

144 in the treatment of constipation predominant irritable bowel syndrome (IBS-C), a highly prevalent dis

145 ogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C).

146 Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) could benefit from a gl

147 Management of diarrhoea-predominant irritable bowel syndrome (IBS-D) is generally based on p

148 efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D).

149 ned diarrhea, including diarrhea-predominant irritable bowel syndrome (IBS-D).

150 hat patients with symptoms of nonconstipated irritable bowel syndrome (NC-IBS) undergo testing for ce

151 04-1.1), diarrhea (OR, 53; 95% CI, 6.1-471), irritable bowel syndrome (OR, 4.8; 95% CI, 1.6-14), chol

152 The existence of postinfection irritable bowel syndrome (PI-IBS) has been substantiated

153 Post-infectious irritable bowel syndrome (PI-IBS) is a common gastrointe

154 Post-infectious Irritable Bowel Syndrome (PI-IBS) is a functional bowel

155 he role of gut microbiota in post-infectious irritable bowel syndrome (PI-IBS) is convincing.

156 actor for the development of post-infectious Irritable Bowel Syndrome (PI-IBS).

157 ith increased rate ratios (RRs) for incident irritable bowel syndrome (RR, 6.1; 95% confidence interv

158 o an online database called Transcriptome of Irritable Bowel Syndrome (TIBS).

159 Of them, 305 (16.5%) had AP-FGD [irritable bowel syndrome = 91(4.9%), functional dyspepsi

160 who are in remission and those who developed irritable bowel syndrome after enteric infection continu

161 in the treatment of constipation-predominant irritable bowel syndrome and chronic constipation.

162 ate the persistence, prevalence, and risk of irritable bowel syndrome and chronic fatigue 6 years aft

163 ing is associated with an increased risk for irritable bowel syndrome and chronic fatigue 6 years lat

164 Although symptomatic irritable bowel syndrome and Crohn's disease patients ha

165 associated with diarrheal conditions such as irritable bowel syndrome and enteric infections.

166 ter, are at increased risk of postinfectious irritable bowel syndrome and inflammatory bowel disease

167 Colon disorders, including irritable bowel syndrome and inflammatory bowel disease,

168 sit and gut microbial communities, including irritable bowel syndrome and inflammatory bowel disease.

169 long-term effects, including postinfectious irritable bowel syndrome and inflammatory bowel disease.

170 , appeared to be most genetically similar to irritable bowel syndrome and most environmentally simila

171 stion that SIBO may be a causative factor in irritable bowel syndrome and of its constituent symptoms

172 successfully treat constipation-predominant irritable bowel syndrome and recent studies show that ex

173 (EPI) confound interpretation of findings in irritable bowel syndrome and severe renal insufficiency.

174 Many treatments for irritable bowel syndrome are available to those with the

175 nt evidence to recommend serologic tests for irritable bowel syndrome at this time.

176 al gastrointestinal disorders, most commonly irritable bowel syndrome but also other functional and o

177 nalities with inflammatory bowel disease and irritable bowel syndrome but were focused on associative

178 In the exposed group, the prevalence of irritable bowel syndrome decreased by 6.7% (RR, 0.85 [95

179 opsies were also taken from 16 patients with irritable bowel syndrome diarrhea who comprised the cont

180 antibiotics and concurrently, postinfectious irritable bowel syndrome has been associated with a long

181 Traditionally, irritable bowel syndrome has been considered to be a dis

182 BEST PRACTICE ADVICE 8: Although irritable bowel syndrome has been shown to respond to th

183 treatment options for diarrhoea-predominant irritable bowel syndrome have had not very promising res

184 microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind,

185 valuate the effectiveness of acupuncture for irritable bowel syndrome in primary care when provided a

186 ased understanding of the pathophysiology of irritable bowel syndrome in the past 10 years has led to

187 Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most n

188 Irritable bowel syndrome is a functional gastrointestina

189 risk factor is acute enteric infection, but irritable bowel syndrome is also more common in people w

190 w we challenge the widely accepted view that irritable bowel syndrome is an unexplained brain-gut dis

191 Irritable bowel syndrome is characterized by altered sen

192 Irritable bowel syndrome is classified as a functional g

193 The pathophysiology of irritable bowel syndrome is incompletely understood, but

194 interventions are enjoying a renaissance in irritable bowel syndrome management.

195 Postinfectious irritable bowel syndrome may occur in 3% to 17% of patie

196 n, Latino individuals, and participants with irritable bowel syndrome or Crohn's disease were more li

197 een the control group and Crohn's disease or irritable bowel syndrome patients in terms Blastocystis

198 Acupuncture for irritable bowel syndrome provided an additional benefit

199 the gut microbiota and the immune system", "irritable bowel syndrome related to gut microbiota", and

200 Patients had a greater reduction in irritable bowel syndrome severity scores following the l

201 ficant difference after 4 weeks in change in irritable bowel syndrome severity scores, but significan

202 Identical irritable bowel syndrome symptoms are probably due to di

203 At 6 months, new diagnoses of irritable bowel syndrome were made in 2 patients (1%) an

204 233 patients with irritable bowel syndrome were randomly allocated to eith

205 ion, 15 with functional bloating, and 3 with irritable bowel syndrome with alternating bowel habits)

206 Irritable bowel syndrome with constipation (IBS-C) affec

207 Patients with irritable bowel syndrome with constipation (IBS-C) and p

208 GC-C) that reduces symptoms associated with irritable bowel syndrome with constipation (IBS-C).

209 C) includes functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C).

210 ipation, chronic idiopathic constipation, or irritable bowel syndrome with constipation is often made

211 ith functional intestinal disorders (27 with irritable bowel syndrome with constipation, 15 with func

212 ed by >2 symptoms of chronic constipation or irritable bowel syndrome with constipation, and with >2

213 tion subtypes of functional constipation and irritable bowel syndrome with constipation.

214 Some patients with irritable bowel syndrome with diarrhea (IBS-D) have inte

215 abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (IBS-D) without c

216 a large proportion of people diagnosed with irritable bowel syndrome with diarrhea, a common functio

217 reased loss of bile acids (BAs), overlapping irritable bowel syndrome with diarrhoea (IBS-D).

218 Chronic idiopathic constipation (CC) and irritable bowel syndrome with predominant constipation (

219 Irritable bowel syndrome with predominant constipation (

220 The term "irritable bowel syndrome" was used to search Clinical Ev

221 chronic fatigue syndrome' and 'Dopamine and irritable bowel syndrome' was carried out until April 20

222 tic syndromes', 'Chronic fatigue syndrome', 'Irritable bowel syndrome', 'Fibromyalgia', 'Dopamine and

223 titial cystitis/painful bladder syndrome and irritable bowel syndrome) are associated with hyperexcit

224 rome, reactive arthritis, and postinfectious irritable bowel syndrome) contribute considerably to the

225 ysiology, etiology, pathogenesis, diagnosis, irritable bowel syndrome, and IBS.

226 broid food poisoning, histamine intolerance, irritable bowel syndrome, and inflammatory bowel disease

227 These include inflammatory bowel diseases, irritable bowel syndrome, and metabolic (i.e. obesity, n

228 robiota, such as inflammatory bowel disease, irritable bowel syndrome, and metabolic syndrome, to nam

229 of work on MGBA focused on immunomodulation, irritable bowel syndrome, and neurodevelopmental disorde

230 owel diseases, celiac disease, food allergy, irritable bowel syndrome, and--more recently recognized-

231 ders, such as inflammatory bowel disease and irritable bowel syndrome, are associated with exaggerate

232 disorders of colonic motor function, such as irritable bowel syndrome, are much more common.

233 disorders (cardiovascular disease, diabetes, irritable bowel syndrome, asthma, and others).

234 to human physiology and to diseases such as irritable bowel syndrome, autism, anxiety, depression, a

235 , management, and role in conditions such as irritable bowel syndrome, chronic fatigue, and autoimmun

236 d costs of ambulatory visits for symptomatic irritable bowel syndrome, chronic functional abdominal p

237 Chronic pain syndromes irritable bowel syndrome, chronic pelvic pain, and fibro

238 pain - is common in some disorders, such as irritable bowel syndrome, Crohn's disease and pancreatit

239 ur findings link duplications in TPSAB1 with irritable bowel syndrome, cutaneous complaints, connecti

240 expanded from 1946 to December 2014 for IBS, irritable bowel syndrome, diet, treatment, and therapy.

241 ted with chronic prostatitis/CPPS, including irritable bowel syndrome, fibromyalgia, and chronic fati

242 r directly co-morbid somatic disorders, e.g. irritable bowel syndrome, fibromyalgia, or migraine.

243 This issue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatme

244 d in the setting of differentiating IBD from irritable bowel syndrome, for grading inflammation, to d

245 nter placebo-controlled trial, children with irritable bowel syndrome, functional abdominal pain, or

246 disorders of gut-brain interaction, comprise irritable bowel syndrome, functional dyspepsia, abdomina

247 unctional gastrointestinal disorder, such as irritable bowel syndrome, functional dyspepsia, or funct

248 mechanisms may predispose the individual to irritable bowel syndrome, gastroesophageal reflux diseas

249 orders including inflammatory bowel disease, irritable bowel syndrome, infectious and antibiotic-asso

250 various gastrointestinal diseases, including irritable bowel syndrome, inflammatory bowel disease, an

251 , including Clostridium difficile infection, irritable bowel syndrome, inflammatory bowel diseases, i

252 hea and colitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and

253 vergrowth is one of the causes suggested for irritable bowel syndrome, particularly for the diarrhoea

254 mens from patients with UC, Crohn's disease, irritable bowel syndrome, sporadic colorectal cancer, or

255 liaison psychiatric setting in patients with irritable bowel syndrome, where positive benefits have b

256 Irritable bowel syndrome, which affects 5-10% of the pop

257 ctional bowel disorders (FBDs), particularly irritable bowel syndrome, with the objective of elucidat

258 est drug to be approved for the treatment of irritable bowel syndrome-diarrhoea is rifaximin, which w

259 sease processes such as neurodegeneration or irritable bowel syndrome.

260 ultimately provide a cure for patients with irritable bowel syndrome.

261 NR1) have been associated with some forms of irritable bowel syndrome.

262 ergrowth participates in the pathogenesis of irritable bowel syndrome.

263 hanced toxin sensitivity in a mouse model of irritable bowel syndrome.

264 psy, ataxia, pain, arrhythmia, myotonia, and irritable bowel syndrome.

265 findings, are nonspecific, and can simulate irritable bowel syndrome.

266 es such as fibromyalgia, chronic fatigue and irritable bowel syndrome.

267 cupuncture is a cost-effective treatment for irritable bowel syndrome.

268 osed inflammatory bowel disease and 877 with irritable bowel syndrome.

269 be cost-effective for those with more severe irritable bowel syndrome.

270 other involving children suffering from the irritable bowel syndrome.

271 tion between infection with Blastocystis and irritable bowel syndrome.

272 rted polymorphisms in the pathophysiology of irritable bowel syndrome.

273 e clearly established a genetic component in irritable bowel syndrome.

274 abdominal pain and cramping in patients with irritable bowel syndrome.

275 and has been implicated in diseases such as irritable bowel syndrome.

276 oms, such as those regarded as components of irritable bowel syndrome.

277 patients with inflammatory bowel disease and irritable bowel syndrome.

278 n, Crohn's disease, and diarrhea-predominant irritable bowel syndrome.

279 nted Gli binding and showed association with irritable bowel syndrome.

280 functional diarrhea and diarrhea-predominant irritable bowel syndrome.

281 onin antagonists have a therapeutic role for irritable bowel syndrome.

282 ing cancer therapies and in the treatment of irritable bowel syndrome.

283 patients with functional diarrhea, including irritable bowel syndrome.

284 , no tests are available to reliably rule in irritable bowel syndrome.

285 ion (95% CI, 2.3-3.2) visits for symptomatic irritable bowel syndrome/chronic abdominal pain, 1.0 mil

286 ed to control (P<.001) and disease controls (irritable bowel syndrome; P<.001; rheumatoid arthritis;

287 searched by using medical subject headings ("irritable bowel syndrome;" "colonic diseases, functional

288 n who do not fit a specific disorder such as irritable bowel, functional dyspepsia, or abdominal migr

289 ior, and neural activity between 19 severely irritable children (operationalized using criteria for s

290 suggest that, relative to healthy children, irritable children have deficient reward learning and el

291 ention flexibility, particularly in severely irritable children, which may contribute to emotion regu

292 levels of positive approach-motivation), and irritable (extreme levels of negative emotionality, ange

293 A greater proportion of patients with the irritable (IR) nociceptor phenotype were responders to i

294 lly and persistently elevated, expansive, or irritable mood and abnormally and persistently increased

295 k the well-demarcated periods of elevated or irritable mood characteristic of bipolar disorder.

296 evels (mean maximum 10,333 IU/liter), and an irritable myopathy on electromyography (88%).

297 EMA3F), number of children (CADM2 and ESR1), irritable temperament (MSRA) and risk-taking propensity

298 The irritable temperament produced the most significant resu

299 emotion dysregulation when very anxious and irritable youth process threat-related faces.

300 angry expressions) may capture attention in irritable youth.